Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary antibody therapeutics, primarily in oncology. The company engages the immune system to treat multiple human diseases, with its scientific orientation centered on the relationship between angiogenesis, the immune system, and tumor growth. Its innovative platform features common light chain-focused antibody discovery, human display technology for antibody tuning, Stitchmabs, and highly modular, manufacturable bispecific antibody candidates. Key product candidates include CTX-009, CTX-471, CTX-10726, VEGF-A bispecifics, and CTX-8371, targeting various aspects of cancer immunotherapy. Compass Therapeutics Inc. operates within the health technology sector, specifically pharmaceuticals, advancing therapies that modulate immune responses against tumors. Founded in 2014 and headquartered in Boston, Massachusetts, the company plays a role in the competitive biopharmaceutical market by pioneering next-generation antibody-based treatments for unmet medical needs in oncology.